BCL2 is a protein that functions as an inhibitor of cell apoptosis (programmed cell death). In malignant cells, the expression of BCL2 protein acts as a biological “brake” against cell death, providing a distinct survival advantage to the cancer cells.
I. Clinical Significance in High-Grade B-Cell Lymphomas
Rearrangements of the BCL2 gene are critical diagnostic and prognostic markers in the classification of aggressive B-cell lymphomas:
- Double-Hit Lymphoma: Characterized by a rearrangement of the MYC gene in addition to a rearrangement of either the BCL2 or BCL6 gene.
- Triple-Hit Lymphoma: Occurs when rearrangements of MYC, BCL2, and BCL6 are all present simultaneously.
- Pathophysiology: While MYC rearrangement promotes rapid tumor proliferation, the BCL2 protein expression inhibits apoptosis, leading to a highly aggressive disease course that often overlaps with the features of Burkitt lymphoma. These lymphomas are associated with very poor clinical outcomes and a higher incidence of central nervous system (CNS) involvement.
II. BCL2 Protein Expression vs. Gene Rearrangement
Oncology pharmacists must distinguish between genetic “hits” and protein expression levels:
- Double Expressor Lymphoma (DEL): This refers to the co-expression of MYC and BCL2 proteins on the cell surface without the underlying genetic rearrangements.
- Prognosis: While DEL is not considered a unique genetic category like “double-hit” lymphoma, it is recognized as a significant adverse prognostic indicator.
III. Therapeutic Implications
Targeting or modulating BCL2 is a key aspect of lymphoma therapy:
- Rituximab: This anti-CD20 monoclonal antibody has been shown to down-regulate Bcl-2 expression, which results in the sensitization of B-cell non-Hodgkin lymphoma cells to cytotoxic drugs.
- Venetoclax: Although not detailed extensively in all protocols, venetoclax is a targeted agent (a BCL2 inhibitor) used in certain settings like relapsed/refractory Mantle Cell Lymphoma.